Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib sequencing in CLL/SLL (BOSS)
NCT06839872Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pirtobrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by AstraZeneca. Planned start Jun 2025; status: withdrawn.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06839872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839872.